welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Michael A. Rudnicki, PhD
Senior Scientist and Director, Regenerative Medicine Program
Ottawa Hospital Research Institute
501 Smyth Box 511
Dr. Michael Rudnicki is a Senior Scientist and the Director of the Regenerative Medicine Program and the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute. He is Professor in the Department of Medicine at the University of Ottawa and the Scientific Director of the Canadian Stem Cell Network.
Dr. Rudnicki is an Officer of the Order of Canada, a Fellow of the Royal Society of Canada, and holds the Canada Research Chair in Molecular Genetics. He is an Associate Editor of Cell Stem Cell and the Journal of Cell Biology, and is Co-Editor in Chief of Skeletal Muscle. He has organized international research conferences as one of the founding directors of the Society for Muscle Biology.
Dr Rudnicki’s laboratory works to understand the molecular mechanisms that regulate the determination, proliferation, and differentiation of stem cells during embryonic development and during tissue regeneration. His lab has conducted leading studies into both embryonic myogenesis and the function of muscle stem cells (satellite cells) in adult regenerative myogenesis. In particular, they have worked extensively to understand the molecular mechanisms that regulate the function of satellite cells in skeletal muscle. His research interests include the population affected with muscular dystrophy and neuromuscular disease.
Carrie Miceli, PhDDr. M. Carrie Miceli is Professor and Vi...
Yvonne StreatfieldYvonne joined the Leeds Neuromuscular te...
Duchenne muscular dystrophy: How muscle cells journey to the dark sidePromoting repair of dystrophic muscles i...
John Brandsema, MDJohn Brandsema, MD, is a pediatric neuro...
Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dyst...Duchenne muscular dystrophy is a rare, p...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...
Sarepta Therapeutics and Genethon announce a gene therapy research collaboration for the treatment of Duchenne muscu...Sarepta Therapeutics, Inc. (NASDAQ:SRPT)...